These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9672847)

  • 1. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
    Chen W; Qin H; Reese VA; Cheever MA
    J Immunother; 1998 Jul; 21(4):257-68. PubMed ID: 9672847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
    Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
    Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell immunity to the joining region of p210BCR-ABL protein.
    Chen W; Peace DJ; Rovira DK; You SG; Cheever MA
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1468-72. PubMed ID: 1346932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
    Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
    Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
    Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
    Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
    Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
    Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
    Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
    Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
    Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
    Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
    Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
    Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL-specific CD4
    Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
    Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
    Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
    Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
    Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
    Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Identification of T cell epitopes of p210(bcr-abl); antigen and detection of epitope-specific CTLs.].
    Zhang J; Wang LH; Gong WJ; Qian YY; Jiang YW; Ji MC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Dec; 25(12):1161-3. PubMed ID: 19961808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
    Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
    J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
    Wagner WM; Ouyang Q; Pawelec G
    Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.
    Mumprecht S; Claus C; Schürch C; Pavelic V; Matter MS; Ochsenbein AF
    Blood; 2009 May; 113(19):4681-9. PubMed ID: 19252140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.